<DOC>
	<DOCNO>NCT00416819</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving rituximab together combination chemotherapy may kill cancer cell . PURPOSE : This clinical trial study side effect best way give combination chemotherapy together rituximab treat patient newly diagnose primary CNS lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Rituximab Treating Patients With Newly Diagnosed Primary CNS Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine rate toxicity , term percentage patient grade 4 neurotoxicity , patient untreated primary CNS lymphoma treat induction therapy comprise high-dose methotrexate , leucovorin calcium , rituximab , temozolomide follow consolidation therapy comprise cytarabine etoposide phosphate . Secondary - Determine efficacy regimen , term 4-month 12-month complete best response rate , patient . - Determine progression-free overall survival patient treat regimen . - Determine percentage patient experience toxicity neurotoxicity due regimen . - Determine treatment-related mortality rate patient treat regimen . - Document neurocognitive change patient use Mini-Mental Status Examination first year treatment regimen . OUTLINE : This pilot , multicenter study . - Induction therapy : Patients receive high-dose methotrexate IV 4 hour day 1,15 , 29 , 43 , 57 , 71 , 99 ; leucovorin calcium IV every 6 hour day 2-4 , 16-18 , 30-32 , 44-46 , 58-60 , 72-74 , 100-102 ; oral temozolomide day 7-11 , 35-39 , 63-67 , 91-95 , 119-123 ; rituximab IV day 3 , 17 , 31 , 45 , 59 , 74 . Treatment continue absence disease progression unacceptable toxicity . Patients achieve complete response proceed consolidation therapy . - Consolidation therapy I : Beginning 3-4 week complete induction therapy , patient receive high-dose methotrexate IV 4 hour day 1 , leucovorin calcium IV every 6 hour day 2-4 , oral temozolomide day 7-11 . - Consolidation therapy II : Beginning 3-5 week complete consolidation therapy I , patient receive cytarabine IV 2 hour twice daily etoposide phosphate IV continuously day 1-4 filgrastim ( G-CSF ) subcutaneously begin day 14 continue blood count recover . After completion study treatment , patient follow periodically 2 year . PROJECTED ACCRUAL : A total 10 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm untreated primary CNS lymphoma ( PCNSL ) confirm 1 follow method : Brain biopsy resection Patients diagnose Tcell PCNSL allow receive rituximab study Cerebrospinal fluid ( CSF ) cytology Positive CSF cytology without measurable intracranial disease Vitreal biopsy Histologic confirmation vitreal lymphoma measurable intracranial tumor No evidence systemic nonHodgkin 's lymphoma CT scan chest , abdomen , pelvis bone marrow biopsy negative extracerebral source lymphoma No evidence pleural effusion ascites MRI brain spine ( plus gadolinium ) must measurable contrast enhance disease unless CSF cytology positive PATIENT CHARACTERISTICS : Karnofsky performance score 50100 % HIV negative Creatinine clearance â‰¥ 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No concurrent salicylates , nonsteroidal antiinflammatory drug , sulfonamide , penicillin within past week</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>primary central nervous system Hodgkin lymphoma</keyword>
</DOC>